Nextcure and the national cancer institute announce preclinical data in journal of clinical investigation

Beltsville, md., april 19, 2022 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a paper titled “remodeling the tumor microenvironment via blockade of lair-1 and tgf-Β signaling enables pd-l1-mediated tumor eradication” in the journal of clinical investigation.
NXTC Ratings Summary
NXTC Quant Ranking